002349 Jinghua Pharmaceutical Group
- 6.98
- +0.02+0.29%
Jinghua Pharmaceutical Group News
Jinghua Pharmaceutical Group: Announcement regarding the consistency evaluation of the company's product phenobarbital tablets as generic drugs.
Jinghua Pharmaceutical Group: Announcement Regarding Sun Company's Approval for Marketing Authorization Application of Chemical Raw Materials as Active Pharmaceutical Ingredients
Jinghua Pharmaceutical Group: Announcement Regarding the Resumption of Sun Company's Production
Jinghua Pharmaceutical Group: Announcement Regarding the Signing of a Framework Agreement with Shanghai Shibei Hi-Tech Industrial Development Zone Management Committee.
Jinghua Pharmaceutical Group: Legal opinion for the first extraordinary shareholder meeting in 2024.
Jinghua Pharmaceutical Group: Announcement of the resolution of the first extraordinary Shareholders' Meeting in 2024.
Jinghua Pharmaceutical Group: Announcement of Annual Equity Distribution Implementation in 2023
Jinghua Pharmaceutical Group: Announcement on the completion of the election of the board of directors and the board of supervisors and the appointment of senior management
Jinghua Pharmaceutical Group: Announcement of Resolutions of the First Meeting of the Sixth Board of Directors
Jinghua Pharmaceutical Group: Announcement of Resolutions of the First Meeting of the Sixth Board of Supervisors
Jinghua Pharmaceutical Group: Announcement on the Notice of Convening the 2024 First Extraordinary General Meeting of Shareholders
Jinghua Pharmaceutical Group: Announcement on the appointment of the company's 2024 accounting firm
Jinghua Pharmaceutical Group: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Jinghua Pharmaceutical Group: 2023 Annual General Meeting of Shareholders Legal Opinions
Jinghua Pharmaceutical Group: 002349 Jinghua Pharmaceutical Investor Relations Management Information 20240510
Jinghua Pharmaceutical Group: 2024 First Quarter Report
Jinghua Pharmaceutical: Letter of commitment from an independent director candidate to participate in independent director training and obtain an independent director qualification certificate
Jinghua Pharmaceutical: 2023 Independent Director Debriefing Report (Ma Ling)
Jinghua Pharmaceutical: Independent Director Nominee Statement and Commitment (Zhang Xiaomei)
Essence Pharmaceuticals: 2023 Annual Report
Analysis
Price Target
No Data
